Enzymotec (Enzymotec) Debt-to-Equity : 0.00 (As of Sep. 2017)

View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Debt-to-Equity?

Enzymotec's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil. Enzymotec's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil. Enzymotec's Total Stockholders Equity for the quarter that ended in Sep. 2017 was $139.43 Mil. Enzymotec's debt to equity for the quarter that ended in Sep. 2017 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Enzymotec's Debt-to-Equity or its related term are showing as below:

ENZY's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Enzymotec Debt-to-Equity Historical Data

The historical data trend for Enzymotec's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec Debt-to-Equity Chart

Enzymotec Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.04

Enzymotec Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Enzymotec's Debt-to-Equity

For the Biotechnology subindustry, Enzymotec's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzymotec's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzymotec's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Enzymotec's Debt-to-Equity falls into.

Enzymotec Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Enzymotec's Debt to Equity Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	136.6
	=	0.00

Enzymotec's Debt to Equity Ratio for the quarter that ended in Sep. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	139.43
	=	0.00

Enzymotec (NAS:ENZY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Enzymotec Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Enzymotec's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzymotec (Enzymotec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.enzymotec.com

Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi • 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon • 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson • 12-07-2015